Quick Answer
REGENXBIO Inc. reported Diluted EPS of $3.76 per share (loss) for fiscal year 2025.
REGENXBIO Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.76 | +18.1% |
| 2024 | -$4.59 | +23.8% |
| 2023 | -$6.02 | +7.4% |
| 2022 | -$6.50 | -323.4% |
| 2021 | $2.91 | +197.7% |
| 2020 | -$2.98 | -15.5% |
| 2019 | -$2.58 | -194.5% |
| 2018 | $2.73 | +211.4% |
| 2017 | -$2.45 | -2.9% |
| 2016 | -$2.38 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.20 | -2.6% | +13.0% |
| June 30, 2025 | -$1.38 | -31.4% | -1250.0% |
| March 31, 2025 | $0.12 | +108.7% | +110.3% |
| September 30, 2024 | -$1.17 | +17.0% | -11.4% |
| June 30, 2024 | -$1.05 | +36.7% | +23.9% |
| March 31, 2024 | -$1.38 | +9.8% | +2.1% |
| September 30, 2023 | -$1.41 | +19.4% | +15.1% |
| June 30, 2023 | -$1.66 | -5.1% | -8.5% |
- REGENXBIO Inc. showed an increase of +18.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, REGENXBIO Inc.’s diluted eps has declined by 58.0% (from $2.38 per share (loss) to $3.76 per share (loss)).
- The most recent figure is from REGENXBIO Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: